US 12209142
SARS-CoV-2 epitope-targeted peptide immunostimulants
granted A61KA61K38/00A61K38/07
Quick answer
US patent 12209142 (SARS-CoV-2 epitope-targeted peptide immunostimulants) held by The United States of America as represented by the Secretary of the Army expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as represented by the Secretary of the Army
- Grant date
- Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61K38/07, A61K38/08, A61K47/55